You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Novartis secures rights to Mesoblast’s remestemcel-L for ARDS

Swiss pharma Novartis has inked an exclusive licence and collaboration agreement with Mesoblast to develop remestemcel-L for acute respiratory distress syndrome (ARDS), including COVID-19-associated ARDS.